EP1605931A4 - Drug formulations having long and medium chain triglycerides - Google Patents
Drug formulations having long and medium chain triglyceridesInfo
- Publication number
- EP1605931A4 EP1605931A4 EP03816401A EP03816401A EP1605931A4 EP 1605931 A4 EP1605931 A4 EP 1605931A4 EP 03816401 A EP03816401 A EP 03816401A EP 03816401 A EP03816401 A EP 03816401A EP 1605931 A4 EP1605931 A4 EP 1605931A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- long
- medium chain
- chain triglycerides
- drug formulations
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45481203P | 2003-03-13 | 2003-03-13 | |
US454812P | 2003-03-13 | ||
PCT/US2003/010533 WO2003086381A1 (en) | 2002-04-10 | 2003-04-04 | Ansamycin formulations and methods for producing and using same |
WOPCT/US03/10533 | 2003-04-04 | ||
US47843003P | 2003-06-12 | 2003-06-12 | |
US478430P | 2003-06-12 | ||
US49105003P | 2003-07-29 | 2003-07-29 | |
US491050P | 2003-07-29 | ||
PCT/US2003/031667 WO2004082676A1 (en) | 2003-03-13 | 2003-10-04 | Drug formulations having long and medium chain triglycerides |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1605931A1 EP1605931A1 (en) | 2005-12-21 |
EP1605931A4 true EP1605931A4 (en) | 2009-04-29 |
Family
ID=35351739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03816401A Withdrawn EP1605931A4 (en) | 2003-03-13 | 2003-10-04 | Drug formulations having long and medium chain triglycerides |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1605931A4 (en) |
JP (1) | JP2006514994A (en) |
CN (1) | CN101756961A (en) |
AU (1) | AU2003277299B2 (en) |
CA (1) | CA2518836A1 (en) |
WO (1) | WO2004082676A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4869077B2 (en) | 2003-12-23 | 2012-02-01 | インフィニティー ディスカヴァリー インコーポレイテッド | Analogs of benzoquinone-containing ansamycins for cancer treatment |
EP1817295B1 (en) | 2004-11-18 | 2012-11-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
CA2596867A1 (en) * | 2005-02-28 | 2006-09-08 | Kosan Biosciences Incorporated | Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin |
CA2603462A1 (en) * | 2005-04-07 | 2006-10-09 | Conforma Therapeutics Corporation | Phospholipid-based pharmaceutical formulations and methods for producing and using same |
EP1874296A4 (en) | 2005-04-29 | 2010-06-30 | Kosan Biosciences Inc | Method of treating multiple myeloma using 17-aag of 17-ag of a prodrug of either |
AU2006338265B2 (en) | 2005-08-18 | 2011-04-14 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
CN101360492A (en) * | 2005-12-01 | 2009-02-04 | 康福玛医药公司 | Compositions containing ansamycin |
PE20081506A1 (en) | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | ANSAMYCIN FORMULATIONS |
WO2010045442A1 (en) | 2008-10-15 | 2010-04-22 | Infinity Discovery, Inc. | Ansamycin hydroquinone compositions |
KR101834577B1 (en) * | 2009-08-14 | 2018-03-05 | 옵코 헬스, 인크. | Intravenous formulations of neurokinin-1 antagonists |
EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
JP2014534228A (en) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | Combination therapy of platinum-containing agents and HSP90 inhibitors |
WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
CN106018611B (en) * | 2016-06-21 | 2018-08-24 | 广州白云山汉方现代药业有限公司 | A kind of assay method of gas chromatogram fixative detection medium chain triglyceride content |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003086381A1 (en) * | 2002-04-10 | 2003-10-23 | Conforma Therapeutics Corporation | Ansamycin formulations and methods for producing and using same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001342A1 (en) * | 1993-06-29 | 1995-01-12 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
US6140374A (en) * | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
DE10036871A1 (en) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersions for the formulation of poorly or poorly soluble active ingredients |
-
2003
- 2003-10-04 JP JP2005513578A patent/JP2006514994A/en active Pending
- 2003-10-04 EP EP03816401A patent/EP1605931A4/en not_active Withdrawn
- 2003-10-04 CA CA002518836A patent/CA2518836A1/en not_active Abandoned
- 2003-10-04 AU AU2003277299A patent/AU2003277299B2/en not_active Ceased
- 2003-10-04 WO PCT/US2003/031667 patent/WO2004082676A1/en active Application Filing
- 2003-10-04 CN CN200910176277A patent/CN101756961A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003086381A1 (en) * | 2002-04-10 | 2003-10-23 | Conforma Therapeutics Corporation | Ansamycin formulations and methods for producing and using same |
Also Published As
Publication number | Publication date |
---|---|
EP1605931A1 (en) | 2005-12-21 |
WO2004082676A1 (en) | 2004-09-30 |
CN101756961A (en) | 2010-06-30 |
AU2003277299A1 (en) | 2004-10-11 |
AU2003277299B2 (en) | 2009-12-10 |
CA2518836A1 (en) | 2004-09-30 |
JP2006514994A (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL170758A0 (en) | 7-amino-isoindolyl compounds and their pharmaceutical uses | |
HK1084883A1 (en) | 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof | |
IL176248A0 (en) | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | |
IL172824A0 (en) | Pharmaceutical formulations | |
GB0302671D0 (en) | Pharmaceutical formulations | |
IL170313A (en) | Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them | |
EP1819746A4 (en) | Tmxdi-based oligomer and formulations containing it | |
HK1088837A1 (en) | Clk-peptide and slk-peptide | |
EP1605931A4 (en) | Drug formulations having long and medium chain triglycerides | |
IL172087A0 (en) | Tetrahydrocarbazole derivatives and their pharmaceutical use | |
PL1655026T3 (en) | Solid pharmaceutical formulations comprising diacereine and meloxicam | |
EP1689629A4 (en) | Wheelchair designs and related enhancements | |
GB0302672D0 (en) | Pharmaceutical formulations | |
GB0316341D0 (en) | Pharmaceutical formulations | |
GB0317877D0 (en) | Pharmaceutical combinations and formulations with improved stability | |
GB0316910D0 (en) | Fluorocombretastatin and derivatives thereof | |
GB0318546D0 (en) | Quinoxalinones and their use | |
GB0300804D0 (en) | Compounds and their use | |
GB0301143D0 (en) | Compounds and their use | |
GB0307231D0 (en) | 7-Nitroindoline derivatives and their uses | |
GB0324912D0 (en) | Pharmaceutical formulations | |
GB0316338D0 (en) | Pharmaceutical formulations | |
GB0326642D0 (en) | Pharmaceutical formulations | |
GB0316343D0 (en) | Pharmaceutical formulations | |
GB0327722D0 (en) | Pharmaceutical formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051004 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BOEHM, MARCUS Inventor name: MANSFIELD, ROBERT Inventor name: ULM, EDGAR, H. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090401 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/00 20060101ALI20090326BHEP Ipc: A61K 47/14 20060101ALI20090326BHEP Ipc: A61K 9/19 20060101ALI20090326BHEP Ipc: A61K 9/107 20060101ALI20090326BHEP Ipc: A61K 31/395 20060101ALI20090326BHEP Ipc: A61K 31/00 20060101ALI20090326BHEP Ipc: A61K 31/33 20060101AFI20041006BHEP |
|
17Q | First examination report despatched |
Effective date: 20090708 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100921 |